Neovacs S.A. (ALNEV.PA)
- Previous Close
0.3099 - Open
0.3190 - Bid --
- Ask --
- Day's Range
0.2900 - 0.3190 - 52 Week Range
0.0001 - 3.2000 - Volume
8,616 - Avg. Volume
1,284,099 - Market Cap (intraday)
115,158 - Beta (5Y Monthly) -868.81
- PE Ratio (TTM)
-- - EPS (TTM)
-35,951.3398 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
www.neovacs.comRelated News
Performance Overview: ALNEV.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALNEV.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALNEV.PA
Valuation Measures
Market Cap
115.16k
Enterprise Value
-2.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
0.00
Enterprise Value/Revenue
-52.23
Enterprise Value/EBITDA
0.70
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-7.49%
Return on Equity (ttm)
-10.43%
Revenue (ttm)
53.48k
Net Income Avi to Common (ttm)
-5M
Diluted EPS (ttm)
-35,951.3398
Balance Sheet and Cash Flow
Total Cash (mrq)
6.19M
Total Debt/Equity (mrq)
3.05%
Levered Free Cash Flow (ttm)
-3.86M
Research Analysis: ALNEV.PA
Company Insights: ALNEV.PA
ALNEV.PA does not have Company Insights